PURPOSE: The aim of this study was to evaluate disease-free survival (DFS), overall survival and toxicity of patients who underwent preoperative therapy for soft tissue sarcoma. MATERIALS AND METHODS: The data of 38 consecutive patients affected by soft tissue sarcoma were retrospectively analysed. Six (15.8 %) patients were treated only with neoadjuvant radiotherapy, and 32 (84.2 %) with neoadjuvant chemo-radiation therapy. Surgery was performed within 4-6 weeks after the completion of neoadjuvant treatment. RESULTS: Median follow-up was 4.9 years (range 1-13.7 years). All patients received preoperative external beam radiotherapy (RT). Most patients (84.2 %) underwent neoadjuvant chemotherapy treatment associated with radiotherapy. After neoadjuvant treatment, the majority of patients underwent wide excision (32 out of 38) and five patients had marginal surgery; only one patient underwent amputation. Local recurrence was observed in only two patients (5.2 %). Fourteen (36.8 %) patients experienced metastatic relapse. At the time of our analysis 13 patients (34.2 %) had died due to metastatic spread of the disease. In our series, DFS in relation to distant metastases (DM) showed a significant result for lower limb involvement (p = 0.038) and marginal excision (p = 0.024), both predictors of a worse DFS, histology was statistically significant although it was not possible to evaluate the risk for specific histology due to the small number of events in the different subtypes. CONCLUSIONS: The results obtained from our study are encouraging with regard to the feasibility and efficacy of preoperative RT in the treatment of soft tissue sarcoma in view of the results obtained in terms of local control, limb sparing and safety.
PURPOSE: The aim of this study was to evaluate disease-free survival (DFS), overall survival and toxicity of patients who underwent preoperative therapy for soft tissue sarcoma. MATERIALS AND METHODS: The data of 38 consecutive patients affected by soft tissue sarcoma were retrospectively analysed. Six (15.8 %) patients were treated only with neoadjuvant radiotherapy, and 32 (84.2 %) with neoadjuvant chemo-radiation therapy. Surgery was performed within 4-6 weeks after the completion of neoadjuvant treatment. RESULTS: Median follow-up was 4.9 years (range 1-13.7 years). All patients received preoperative external beam radiotherapy (RT). Most patients (84.2 %) underwent neoadjuvant chemotherapy treatment associated with radiotherapy. After neoadjuvant treatment, the majority of patients underwent wide excision (32 out of 38) and five patients had marginal surgery; only one patient underwent amputation. Local recurrence was observed in only two patients (5.2 %). Fourteen (36.8 %) patients experienced metastatic relapse. At the time of our analysis 13 patients (34.2 %) had died due to metastatic spread of the disease. In our series, DFS in relation to distant metastases (DM) showed a significant result for lower limb involvement (p = 0.038) and marginal excision (p = 0.024), both predictors of a worse DFS, histology was statistically significant although it was not possible to evaluate the risk for specific histology due to the small number of events in the different subtypes. CONCLUSIONS: The results obtained from our study are encouraging with regard to the feasibility and efficacy of preoperative RT in the treatment of soft tissue sarcoma in view of the results obtained in terms of local control, limb sparing and safety.
Authors: J M Coindre; P Terrier; N B Bui; F Bonichon; F Collin; V Le Doussal; A M Mandard; M O Vilain; J Jacquemier; H Duplay; X Sastre; C Barlier; M Henry-Amar; J Macé-Lesech; G Contesso Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: Nabil Wasif; Robert M Tamurian; Scott Christensen; Ly Do; Steve R Martinez; Steven L Chen; Robert J Canter Journal: Ann Surg Oncol Date: 2011-07-16 Impact factor: 5.344
Authors: A M Davis; B O'Sullivan; R S Bell; R Turcotte; C N Catton; J S Wunder; P Chabot; A Hammond; V Benk; M Isler; C Freeman; K Goddard; A Bezjak; R A Kandel; A Sadura; A Day; K James; D Tu; J Pater; B Zee Journal: J Clin Oncol Date: 2002-11-15 Impact factor: 44.544
Authors: D M Brizel; S P Scully; J M Harrelson; L J Layfield; J M Bean; L R Prosnitz; M W Dewhirst Journal: Cancer Res Date: 1996-03-01 Impact factor: 12.701
Authors: A N Wilson; A Davis; R S Bell; B O'Sullivan; C Catton; F Madadi; R Kandel; V L Fornasier Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Kelly K Curtis; Jonathan B Ashman; Christopher P Beauchamp; Adam J Schwartz; Matthew D Callister; Amylou C Dueck; Leonard L Gunderson; Tom R Fitch Journal: Radiat Oncol Date: 2011-08-09 Impact factor: 3.481
Authors: Riikka Nevala; Erkki Tukiainen; Maija Tarkkanen; Tom Böhling; Carl Blomqvist; Mika Sampo Journal: Sci Rep Date: 2019-05-13 Impact factor: 4.379